T
The Carlyle Group Inc.
+ HoldingOPT
-6.13%
3M Return
$3.410
+0.247 (+7.23%)Zum Schluss
Loading chart…
- High
- 3.480
- Open
- 3.480
- VWAP
- 3.38
- Vol
- 3.02K
- Mkt Cap
- 167.31M
- Low
- 3.250
- Amount
- 10.22K
- EV/EBITDA, TTM
- -4.32
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Bewertungskennzahlen
The current forward P/E ratio for Opthea Ltd (OPT) is -11.42, compared to its 5-year average forward P/E of -3.69.
Whales holding OPT
Event-Zeitleiste
News
6.505-27Yahoo FinanceAnalysis of High Insider Ownership Growth Companies in the UK
6.504-06Yahoo FinanceAnalysis of High Insider Ownership Growth Companies in the UK
6.501-22Yahoo FinanceAnalysis of High Insider Ownership Growth Companies in the UK
2.001-21Yahoo Finance10 Undervalued Stocks in the UK Market Amid Weak Trade Data
3.501-08GlobenewswireOptimove Launches AI Marketing Tools Hub, Boosting Campaign Execution Speed by 88%
OPT FAQ — answered by Alphio AI
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.